Physician profile
Matthew Nessetti
NPI 1568409407
$15,766.66
in general payments reported to CMS, 2019-2025
45 companies · $1,230 in 2025
The $1,230 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $381 · 2020: $602 · 2021: $1,691 · 2022: $9,445 · 2023: $1,317 · 2024: $1,100 · 2025: $1,230.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,120 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $527.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,120.44 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $526.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $7,614.14 | 2020-2025 | Rexulti |
| Neuronetics, INC. | $1,832.66 | 2020-2024 | Neurostar Tms Therapy System |
| Abbvie INC. | $999.86 | 2021-2025 | |
| Novo Nordisk INC | $818.33 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Pfizer INC. | $501.12 | 2019-2025 | |
| Lilly USA, LLC | $478.39 | 2019-2025 | Zepbound, Mounjaro |
| Tris Pharma INC | $446.67 | 2021-2025 | Dyanavel Xr |
| Indivior INC. | $334.77 | 2019-2025 | Sublocade |
| Supernus Pharmaceuticals, INC. | $219.87 | 2021-2023 | Xyosted, Tlando, Qelbree |
| Astrazeneca Pharmaceuticals LP | $216.75 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Astellas Pharma US INC | $209.77 | 2019-2021 | |
| Tempus Ai, INC | $183.89 | 2024 | |
| Vanda Pharmaceuticals INC. | $182.89 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $180.14 | 2020-2022 | |
| Biogen, INC. | $150.22 | 2020-2021 |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $120.80 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $108.95 | 2019-2022 | |
| Hologic Sales and Service, LLC | $104.02 | 2022-2024 | Thinprep 2000 Processor, Aptima |
| Janssen Pharmaceuticals, INC | $95.46 | 2019-2025 | Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $93.11 | 2024 | Caplyta |
| Allergan, INC. | $82.14 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $79.32 | 2021-2023 | |
| Exact Sciences Corporation | $71.05 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Antares Pharma, INC. | $65.70 | 2019-2025 | Xyosted, Tlando, Nocdurna |
| Abbott Laboratories | $49.25 | 2019-2024 | Proclaim |
| Shield Therapeutics INC | $46.70 | 2024-2025 | |
| Nestle Healthcare Nutrition INC. | $41.33 | 2020-2021 | |
| Idorsia Pharmaceuticals US INC | $40.85 | 2024 | Quviviq |
| Phadia US INC. | $39.79 | 2019-2023 | Immunocap |
| Livanova USA, INC. | $37.64 | 2021 | |
| Halozyme INC | $33.25 | 2023 | |
| Nevro Corp. | $32.52 | 2023-2024 | Senza |
| Sunovion Pharmaceuticals INC. | $32.23 | 2019-2020 | |
| Fidia Pharma USA INC. | $28.74 | 2023-2025 | Triluron, Hymovis |
| Zyla Life Sciences, INC. | $25.01 | 2019 | |
| Therapeuticsmd, INC. | $23.86 | 2019 | |
| Philips North America LLC | $21.41 | 2025 | Diagnostic Ecg Service |
| Strata Skin Sciences, INC. | $21.27 | 2025 | Xtrac |
| Dexcom, INC. | $17.65 | 2021 | |
| Phathom Pharmaceuticals, INC. | $16.59 | 2025 | Voquezna |
| Horizon Therapeutics Plc | $16.43 | 2023 | Krystexxa |
| Merck Sharp & Dohme LLC | $15.22 | 2022 | |
| Jazz Pharmaceuticals INC. | $13.31 | 2021 | |
| Currax Pharmaceuticals LLC | $12.39 | 2021 | |
| Ethicon US, LLC | $11.20 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Nessetti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.